Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy

Diabetes Technology and Therapeutics

Volumn 17, Issue 7, 2015, Pages 468-474

  Chiefari, Eusebio ^a   Capula, Carmelo ^a   Vero, Ada ^a   Oliverio, Rosa ^a   Puccio, Luigi ^a   Liguori, Rossella ^a   Pullano, Vittorio ^a   Greco, Manfredi ^b   Foti, Daniela ^a   Tirinato, Domenico ^c   Vero, Raffaella ^a   Brunetti, Antonio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c Catanzaro Provincial Health Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FASTING PLASMA GLUCOSE; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INFECTION; ITALIAN (CITIZEN); KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETROSPECTIVE STUDY; SKIN DISEASE; SUBCUTANEOUS FAT DISORDER; SYSTOLIC BLOOD PRESSURE; THORAX DISEASE; URINARY TRACT DISEASE; VOMITING; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANALYSIS; BLOOD; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EVALUATION STUDY; MIDDLE AGED; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84982732820     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0412     Document Type: Article

References (29)

1. Danaei G, Finucane MM, Lu Y, et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31-40.
2. Peters KR: Liraglutide for the treatment of type 2 diabetes: a clinical update. Am J Ther 2013;20:178-188.
3. Pratley RE, Nauck MA, Barnett AH, et al.: Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2014;2:289-297.
4. Ryan GJ, Foster KT, Jobe LJ: Review of the therapeutic uses of liraglutide. Clin Ther 2011;33:793-811.
5. Davies MJ, Kela R, Khunti K: Liraglutide-overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2011;13:207-220.
6. Vilsbøll T, Christensen M, Junker AE, et al.: Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771.
7. Briscoe VJ, Griffith ML, Davis SN: The role of glimepiride in the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 201;6:225-235.
8. American Diabetes Association: Standards of medical care in diabetes-2014. Diabetes Care 2014;37(Suppl 1):S14-S80.
9. Henry RR, Buse JB, Sesti G, et al.: Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1C: a meta-analysis of the liraglutide development program. Endocr Pract 2011;17:906-913.
10. Fadini GP, Simioni N, Frison V, et al. Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol 2013;50:943-949.
11. Chiefari E, Tanyolaç S, Iiritano S, et al.: A polymorphism of HMGA1 is associated with increased risk of metabolic syndrome and related components. Sci Rep 2013;3:1491.
12. Di Gaetano C, Voglino F, Guarrera S, et al.: An overview of the genetic structure within the Italian population from genome-wide data. PLoS One 2012;7:e43759.
13. Legato MJ, Gelzer A, Goland R, et al.: Gender-specific care of the patient with diabetes: review and recommendations. Gend Med 2006;3:131-158.
14. Jendle J, Nauck MA, Matthews DR, et al.: Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163-1172.
15. Garber A, Henry RR, Ratner R, et al.: Liraglutide, a oncedaily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13:348-356.
16. Yang W, Chen L, Ji Q, et al.: Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes Metab 2011;13:81-88.
17. Rigato M, Fadini GP: Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2014;7:107-120.
18. Rosenstock J, Samols E, Muchmore DB, Schneider J: Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996;19:1194-1199.
19. Derosa G, Gaddi AV, Piccinni MN, et al.: Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial. Diabetes Obes Metab 2006;8:197-205.
20. Valsaraj S, Augusti KT, Chemmanam V, et al.: Effects of insulin, glimepiride and combination therapy of insulin and metformin on blood sugar and lipid profile of NIDDM patients. Indian J Clin Biochem 2009;24:175-178.
21. Robinson LE, Holt TA, Rees K, et al.: Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ 2013; 3:e001986.
22. Pratley R, Nauck M, Bailey T, et al.: One year of liraglutide treatment of fers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011;65:397-407.
23. Jeong KH, Yoo BK: The efficacy and safety of liraglutide. Int J Clin Pharm 2011;33:740-749.
24. Nauck M, Frid A, Hermansen K, et al.: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84-90.
25. Bode BW, Testa MA, Magwire M, et al.: Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:604-612.
26. Nauck M, Marre M: Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med 2009;121:5-15.
27. Nauck M, Frid A, Hermansen K, et al.: Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 2013;15:204-212.
28. Garber A, Henry R, Ratner R, et al.: Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
29. Tzanetakos C, MelidonisA, Verras C, et al.: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv Res 2014;14:419.